CXCL10 and metabolic dysfunction-associated steatotic liver disease: A transcriptome analysis of RNA from plasma and liver biopsies in separate cohorts with NAFLD showed a statistical upregulation of osteopontin (SPP1) and CXCL10, serving as a potential biomarker of NAFLD [102].